Advocacy Day 2013 bolstered by the support of industry leaders
The seventh annual Pancreatic Cancer Advocacy Day will be held in Washington, D.C., on June 17 and 18, 2013. In addition to celebrating the passage of the historic Recalcitrant Cancer Research Act earlier this year, the hundreds of advocates gathered for the event will educate their elected officials about the impact budget cuts could have on cancer research and what they can do to protect research funding.
Advocacy Day is the largest single gathering of people committed to fighting pancreatic cancer – patients, survivors, caregivers, family members, researchers and health care professionals. Participants come from all 50 states to learn about the disease, gain support, and meet with their members of Congress. The event is empowering and vital to the success of pancreatic cancer researchers everywhere working to help find a cure.
Sponsorship is critical to the continued success of the event, so we are incredibly grateful to our sponsors Celgene and Merrimack for the generous support they are providing to us this year. For more information about our advocacy program, visit www.pancan.org/advocate.
Please scroll down to learn more about some of our sponsors.
“What unites Celgene with the Pancreatic Cancer Action Network is a shared sense of purpose: to empower patients and their loved ones and provide them with hope. We are proud to join our voice with yours, during Advocacy Day and beyond to help elevate the issues important to people impacted by pancreatic cancer and make a difference.”
Celgene Vice President, Patient Advocacy
To learn more about Celgene, visit www.celgene.com.
“Merrimack is proud to sponsor Advocacy Day and support the pancreatic cancer community. Our employees are committed to the fight against cancer and enthusiastically participated in PurpleStride Boston last year. We are delighted to become a part of the Pancreatic Cancer Action Network’s family of Industry Champions.”
Merrimack Program Leader
To find out more about Merrimack and its efforts to expand pancreatic cancer treatment options where few alternatives now exist, visit www.merrimackpharma.com.